Philips Launches ECG AI Marketplace to Enhance Early Cardiac Diagnosis
July 17, 2025
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips' ECG ecosystem
CAMBRIDGE, Mass. — Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the launch of the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily. Anumana, an AI-driven health technology company committed to transforming the continuum of cardiac care, is the first organization to leverage Philips' platform. Its FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm will be available in the Philips ECG AI Marketplace.
As clinicians become more comfortable using AI-powered tools, healthcare organizations have adopted multiple vendors' platforms and solutions. The Philips ECG AI Marketplace enables U.S. hospitals and health systems to integrate validated algorithms into their workflow and existing Philips infrastructure. The Marketplace also gives cardiac care teams direct access to a broad portfolio of AI tools at the point of care, helping reduce the time it takes for clinicians to review ECG results and fast-track diagnoses for patients. The platform's ability to manage vendor connections for each AI solution also improves operational costs and efficiency by removing the need to devote hospital IT resources to overseeing the different interfaces for every tool.
"Through the Philips ECG AI Marketplace, we're building a more flexible and connected approach to innovation in cardiac care," said Stefano Folli, Business Leader, Ambulatory Monitoring and Diagnostics, Philips. "The Philips ECG AI Marketplace meets a growing need for easier access and management of AI-enabled tools to improve the healthcare experience for clinicians and patients. Our collaboration with Anumana is a strong example of how these tools can support both earlier detection of heart diseases and accelerate patient care."
Anumana's FDA breakthrough-designated LEF algorithm is now integrated across Philips' ECG portfolio through the Philips ECG AI Marketplace, including IntelliSpace ECG and Philips cardiographs. The LEF algorithm analyzes a standard 12-lead resting ECG to identify reduced ejection fraction, an early indicator of heart failure. With Anumana's algorithm now available through the Philips ECG AI Marketplace, healthcare providers can access AI-powered cardiac insights during routine ECG ordering and interpretation, supporting timely and informed care.
"We're proud to be the flagship offering on the Philips ECG AI Marketplace," said Simos Kedikoglou, MD, President and Chief Operating Officer at Anumana. "Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance. Anumana's AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications. By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure."
The collaboration with Anumana is part of the continuing expansion by Philips to open its ECG ecosystem to third-party solutions, to ease integration and support clinical decision-making. By making AI diagnostics more available to cardiac care teams, Philips aims to improve access to early cardiovascular disease detection and care.
For further information, please contact:
Philips
Allison Johnson
Director, Monitoring Communications
Tel: +1 617-631-7305
E-mail: [email protected]
About Royal Philips
Royal Philips (NYSE:PHG, AEX: PHIA)) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
